ICON plc to present at upcoming Investor Conferences
ICON plc today announced that Mr. Brendan Brennan, CFO of ICON plc, will present at the Jefferies London Healthcare Conference and at the Evercore HealthCONx Conference.
ICON Reports Third Quarter 2023 Results
Quarter three revenue of $2,055.1 million representing an increase of 5.8% on prior year revenue.
ICON Secures Upgraded Credit Rating from S&P Global Ratings
ICON plc today announced that S&P Global Ratings (S&P) upgraded ICON to an investment grade credit rating of BBB- with a stable outlook, based on operating performance and deleveraging.
ICON Schedules Third Quarter 2023 Earnings Conference Call
ICON plc announced that it will release its financial results for the third quarter 2023 after the market closes on Wednesday, October 25, 2023.
ICON releases expanded end-to-end Clinical Trial Tokenisation solution
ICON announces the release of its next generation Clinical Trial Tokenisation solution.
BARDA partners with ICON to execute next generation COVID-19 vaccines clinical trial
ICON plc today announces that it is partnering with BARDA to execute a clinical trial to evaluate the effectiveness of next generation COVID-19 vaccine candidates.
ICON plc to Present at the Baird Global Healthcare Conference
ICON plc today announced that Dr. Steve Cutler, CEO of ICON plc, will present at the Baird Global Healthcare Conference on Wednesday, September 13, 2023.
ICON Shareholders Vote in Favour of All Resolutions at its Annual General Meeting
All resolutions at the Annual General Meeting of the Company (AGM) held on July 25, 2023 were all duly passed by shareholders.
ICON Reports Second Quarter 2023 Results
Net business wins in the quarter of $2,419 million; a net book to bill of 1.20 or 1.21 on a trailing twelve month basis.
ICON recognised for CRO excellence
Industry awards as an employer of choice and for its creative and digital services.